The FDA approved Telix Pharmaceuticals' Pixclara (TLX101-Px). Utilizing 18F-FET to target LAT1 and LAT2 amino acid transporters, the radiotracer distinguishes recurrent brain glioma from radiation nec…
🧠 LAT1/LAT2 Selective Uptake: Enters high-grade glioma cells with high tumor-to-brain ratio, enabling definitive delineation of active margins.
🏥 Resolving Pseudoprogression: Replaces ambiguous contrast enhancement on conventional gadolinium MRI with direct metabolic imaging.
Brand Name: Pixclara® (TLX101-Px, 18F-FET)
Regulatory Status: FDA Approved (September 2026)
Mechanism: LAT1/LAT2 amino acid transporter uptake
Clinical Population: Adult and pediatric glioma patients
The FDA approved Telix Pharmaceuticals' Pixclara (TLX101-Px). Utilizing 18F-FET to target LAT1 and LAT2 amino acid transporters, the radiotracer distinguishes recurrent brain glioma from radiation necrosis with 94% diagnostic accuracy.
Eliminates diagnostic ambiguity, protecting patients from invasive craniotomies or premature cessation of viable anticancer therapies.
Regulatory frameworks and infrastructure readiness remain critical.
By 2028, amino-acid PET will supersede contrast-enhanced MRI as the definitive post-treatment monitoring standard in neuro-oncology.